CONGRESS MATERIALS

Medical Information
Hong Kong
 
This website is intended only for healthcare professionals in the Hong Kong Special Administrative Region (HKSAR). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.
 

Please choose the category that best describes you.

I am a Healthcare Professional in the HKSARYes, I am a healthcare professional
SelectI am a Healthcare Professional in the HKSARYes, I am a healthcare professional
I am NOT a Healthcare ProfessionalNo, go back to the patient portal
SelectI am NOT a Healthcare ProfessionalNo, go back to the patient portal

I am a healthcare professional in another country

CONGRESS MATERIALS

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the local Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the local approved Prescribing Information. Where the product is not marketed in Hong Kong, all information in this document is off-label.
Poster
Rubin DT, Vavricka SR, Armuzzi A, Dubinsky MC, Sharara AI, Modesto I, Fellmann M, Liguori G, Lawendy N, Cadatal MJ, Lichtenstein GR May 24, 2022 DDW 2022 Ulcerative Colitis

Efficacy and safety of tofacitinib in ulcerative colitis patients with extraintestinal manifestations in OCTAVE Open

View Presentation
Oral Presentation
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panés J, Yarur A, Ritter T, Baert F, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG May 24, 2022 DDW 2022 Ulcerative Colitis

Etrasimod 2 mg Once Daily as Treatment for Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials

View Presentation
Oral Presentation
Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Guo X, Mundayat R, Su C, Panés J May 24, 2022 DDW 2022 Ulcerative Colitis

Tofacitinib for the treatment of ulcerative colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials

View Presentation